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Abstract 
The world is being mauled by chronic illnesses and the ever-rising costs of healthcare. Researchers in  
the field of healthcare agree that chronic illnesses are mostly by their nature preventable. Despite all,  
preventive healthcare seems to not attract the interest amongst decision makers and aren’t 
provided to the public nearly as much as curative healthcare services are. This literature review focuses 
on providing a wireframe like image of how economic evaluation is being conducted in the field  
of healthcare. This is done by introducing the most common tools thoroughly: COI, PCA, CEA, 
CUA and CBA, how these tools differ compared with one another and the limitations and assumptions  
that these tools and the current research methods face. By introducing these tools, and their limitations 
in capturing essential value and effectiveness of prevention, such as, preventions role in decreasing  
other co-morbidities and the effect of potential spillover effects, we look to encourage the further  
development of the existing process of conducting economic evaluation in the field of healthcare.  
Firstly, we assume that by all stakeholders in the field adopting a universal language of measuring 
cost-efficiency of prevention, and breaking a potential barrier of communication would result in wider 
adaption of prevention. Secondly by taking into consideration and by implementing the limitations of  
the tools currently used to develop future models, prevention effectiveness calculations in terms of  
their increased cost-efficiency could be presented in a better light to the deciding policymakers and  
would gain more interest amongst these stakeholders, which would ideally result in the increased  
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One of the biggest topics of interest globally amongst policymakers and researchers in the 
field of healthcare is the ever-rising cost of healthcare and the exponentially rising percentage 
of the population suffering from various kinds of chronic illnesses. According to OECD 
statistics expenditure in healthcare has grown almost 25% in the past 20 years. 
Simultaneously, chronic illnesses are becoming more typical which are by their nature, 
preventable (Cohen & Neuman 2009). According to Wang (2018) chronic illnesses account 
for 60% of all deaths that occur in modern society. This makes chronic illnesses one of 
humankind's biggest threats. The threat that chronic illnesses pose towards modern society 
has grown into being a major topic of interest in the community of researchers, health 
economists and national organizations. Together these stakeholders are looking at ways that 
these diseases could be prevented. They aim to build strong economic cases to inform and 
reassure policymakers of the potential of preventive healthcare. Such studies have been 
conducted by multiple national organizations and researchers globally, such as McDaid et al. 
(2015) ; Haddix, et al. (2013) ; Cohen & Neumann (2009).  
 
The cost-effectiveness of prevention is dividing opinions amongst the public. Some studies 
claim that preventive health care might not cut costs and thus the wide adaptation of 
preventive healthcare might not be beneficial, potentially increasing the total healthcare costs 
(Cohen et al. 2008). This has risen the interest of researchers in the field of health economics 
to study the tools of how economic evaluation generally in healthcare is being conducted and 
finding limitations of the current tools and study designs. By doing so, researchers in the field 
are looking to find value that is currently being excluded from these studies and thus 
developing better, more accurate methods for the use of researchers and policymakers. With 
developed more accurate tools and methods researchers are looking to shape the whole 
picture of the potential value that prevention might bring and thus engage a wider adaptation 
of prevention.  
 
In this literature review, I look to examine how economic evaluation in the field of health 
care is conducted and tie this field of science into the observations and increased attention 
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towards the need of increasing the amount of preventive healthcare services. I look to study if 
partly the slow and moderately low adoption of preventive healthcare services might be 
caused by the limitations of these analysis methods used. Hypothetically, I assume that 
current research on the economic evaluation of preventative healthcare lacks the ability to 
fully capture the value that preventative healthcare would bring to society, and that 
unobserved value might be the reason for low cost-effectiveness found by multiple studies in 
the field.   
 
 
I’ll start this process by analyzing the distribution and development of preventive healthcare 
in developed countries. Secondly, I’ll show how the burden of disease is validated to a given 
economy, and how potential costs of an intervention is thus being formed and what costs are 
taken into consideration when conducting such studies. In the third chapter, I look to show 
the analysis methods the researchers in the field are using in measuring the effectiveness of 
preventive interventions. How these methods differ from each other and, what models have 
reached the widest adaptation and why these models hold better in analyzing cost-
effectiveness. In the fourth chapter I look to reveal the limitations of these methods, what 
benefits or increased effectivity these models don’t take into consideration that could, if taken 












2. Definition, distribution and the development of preventive 
and curative health care 
2.1 Definition of preventive and curative healthcare 
 
According to the World Health Organizations definition, preventive health care services can 
be divided into two subcategories – primary and secondary prevention. Primary prevention is 
defined as; “actions aimed at avoiding the manifestation of a disease” (WHO). This may 
include introducing new policies or education in changing the impact of social and economic 
determinants on health from an individual or communal level. Such interventions can be for 
example: nutritional and food supplementation, oral health, and dental hygiene or certain 
preventive interventions for individuals with communicable diseases. Secondary prevention 
is defined as early diagnosis and treatment of diseases that are still in the very early stages. 
Clinical examples of services that are in the realm of secondary prevention can be evidence-
based screening for potential risk group for certain diseases from a population (WHO).  
 
Preventive health care is a broad term that covers multiple levels and ways of reducing the 
likelihood of incidence of a disease. The term can include treatments varying from 
vaccination against polio to advanced regulation in the usage of seat belts, dietary restrictions 
and regulation in primary schools (Goetzel 2009).  
 
Curative or rehabilitative care refers to medical practices in order to treat patients with 
existing diseases and helping to reach an optimal physical, sensory, intellectual, 
psychological and social function (OECD). Curative healthcare is optionally also referred to 







2.2 Current distribution of preventive and curative healthcare services  
Distribution of healthcare between preventive and curative treatment methods in developed 
countries is significantly uneven. According to Wang (2018) the distribution of preventive 
and curative treatment varies significantly in developed countries. Wang conducted a study 
which looked at the distribution of preventive and curative treatment expenditure of the total 
healthcare costs relative to Gross Domestic Product (GDP), in 29 of all 36 OECD member 
countries. The expenditure of preventive and curative care was observed over the time period 
of 1998 to 2013 and an average estimate of the shares of expenditure between preventive and 
curative healthcare was formed from the data. The expenditure on preventive healthcare was 
the highest in New Zealand with 0.7% of GDP and lowest in the Slovak Republic, which was 
close to zero, 0.001%. Simultaneously, the expenditure of curative care was the highest in the 
United States 15.91% and lowest in South Korea at 3.62%. Looking solely at The United 
States which globally represents one of the biggest health care capitals in the world, their 
share in preventive health care services simultaneously in the same time period was 
approximately 0.5% of GDP (OECD statistics). This would mean that the U.S., representing 
one of the biggest health care countries, spends approximately 31 times more in treatment-
based health care services, than preventive health care services.  
 
2.3 Recent development of preventive and curative healthcare services 
 
Development of healthcare, in general, has grown significantly in the 2000s. The expenditure 
of healthcare in OECD countries grew from 2000 to 2017 by 23.6%. While at the same time 
the GDP in OECD countries two-folded (OECD statistics). Reasons for the growth of health 
care expenditure is usually explained by the growth of the aging population in developed 
countries and increased amount of non-communicable diseases and chronic illnesses.   
 
According to Wang (2018) the development of preventive and curative health care has grown 
steadily in the past two decades in the previously mentioned OECD countries, prevention 
growing slower. The expenditure of curative healthcare from 1998 to 2013 grew from 7.62% 
to 9.08% on average. While preventive health care grew from 0.23% to 0.26% on average. 
Looking at the U.S. alone, the share of preventive healthcare expenditure over the past 20 
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years has slowly declined. The share of U.S.  expenditure in preventive health care has 
declined from 1999 (3.99%) to 2013 (3.09%) (Wang et al. 2016). At the same time, The U.S. 
GDP per capita from 1999 to 2013 grew from 34478.0 to 53016.3 U.S. dollars (OECD 
statistics). Even though the GDP per capita has grown in the U.S. the supply of preventive 
healthcare services has not grown, but instead declined. These findings seem to be conflicted 
with findings conducted by many researchers. Even Wang’s later conducted studies, which 
studied how the growth of GDP is positively correlated with the growth of preventive health 
care services after exceeding certain GDP per capita threshold. Developed countries, 
including the U.S. have by far passed this threshold. Simultaneously curative health care 
expenditure grew in the U.S from 1999 to 2013 by 30.4% (OECD statistics).  
 
These findings indicate that the development of preventive healthcare services in developed 
countries seems to be increasing but by a much slower pace than curative health care 
services. In one of the biggest health care sectors in the world, The U.S., preventive 
healthcare services are declining, and far more resources are invested in curative treatment 
services.  
 
3. Methods of measuring the effectiveness of preventive 
healthcare interventions 
3.1 Economic Evaluation 
Economic evaluation is a stack of tools for analyzing which of the diseases and conditions in 
the general population are being the costliest to the society (Cost of Illness analysis). By 
comparing diseases and the associated costs with one another, economic evaluation looks to 
discover the most cost-effective way of treating a disease or condition. With limited 
resources, economists and policymakers agree on the fact that maximizing the population’s 
health is important, but in the realm of scarce resources maximizing population’s health, 
investing in healthcare must be done in a way that simultaneously minimizes the costs and 
maximizes the potential benefits. Economic evaluation helps us to understand the costs and 
the possible benefits of introducing a new intervention in healthcare. The needed tools in 
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regard to understand the process of economic evaluation are presented in the following 
sections.  
 
3.1.1 Cost-of-illness analysis (COI) 
The first type of economic evaluation prior to the intervention is referred as economic impact 
analysis or often addressed among researchers in the field as Cost-of-illness analysis (COI). 
This analysis looks to discover the total cost of an existing disease or illness with the pre-
existing ways of treating the disease, for example, costs occurring due to obesity in developed 
countries on a specific time frame. These calculations of costs usually take into consideration 
according to Haddix et al. (2013):  
 
• Cost of direct medical expenses for the disease 
• Cost of direct non-medical resources associated with the disease 
• Indirect costs such as loss in productivity 
 
COI works as a tool for policymakers and researchers in finding which diseases are the most 
costly and potentially hold a threat of having a wide impact on the population’s health in the 
future, cause inefficiencies in the economic landscape in terms of lost productivity and it well 
indicates how health care resources are currently being allocated to different diseases and 
conditions. For example, in 1990 in the U.S. the cost of obesity was estimated to be around 
68,800 million dollars with direct costs accounting for 67,3% including the high potential of 
obesity-associated risks and the remaining part 33.3% accounting for indirect costs that were 
mainly due to the loss in productivity (Wolf & Colditz 1994). COI is used in order to 
compare the burden of a variety of diseases in a given society with each other and can be 
used as a tool for policymakers and researchers for arguing and justifying the need for a 
possible intervention for certain diseases or improvements in the current treatments methods 
due to its high costs to the society (Haddix et al. 2013).  
 
3.1.2 Programmatic cost analysis (PCA) 
After defining the COI of certain disease or condition in a given society on a specific time 
frame a detailed programmatic cost analysis (PCA) needs to be conducted. Programmatic 
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cost analysis is used to define all the costs associated in a certain intervention for existing 
disease or condition that is seen worthwhile after previously introduced COI analysis. 
Programmatic costs can be divided into two subcategories (CDCb). Financial costs are all the 
costs or expenditure on resources that can be valued based on a market price. These are 
resources that are needed in order to implement the intervention, such as R&D, salary and 
supply costs. Economic costs are costs that don’t necessarily have a market price but need to 
be included in the calculations in order to form more accurate cost estimates of the total costs 
implementing the program. For example, a given hospital could use a volunteering nurse 
appointed to the intervention program in other tasks that would accumulate value to the 
hospital. In order to capture all of the costs associated with the intervention, researchers need 
to use multiple sources and ways of analyzing the potential costs of resources. Salaries of 
personnel participating can be derived from accounting and payroll systems often on a highly 
detailed level. Cost of facilities and machinery usually hold a market price. Additionally, 
researchers can evaluate economic costs using questionnaires and observational data from the 
participants taking part in the experiment. Such economic costs could be for example 
traveling time to the research site or waiting time to treatment due to the low supply of the 
given treatment in its test phases.  
 
After accurate estimation of the financial and economic costs associated with a program or 
intervention, we can move into comparing firstly the status quo treatment to a given 
intervention. Secondly comparing different interventions looking to tackle a given disease or 
condition with various ways of treatment with each other. Through comparing multiple 
interventions with one another, finally finding the best possible intervention that presents the 
most favorable cost saving or cost-effectiveness potential.  
 
3.2 Prevention-effectiveness analysis methods 
The purpose of prevention-effectiveness analysis is to analyze the cost-effectiveness of a 
preventive intervention with the status quo treatment methods and to identify, measure, value 
and compare different possible interventions with each other. These analysis methods can be 
divided into two categories. Cost-effectiveness analysis (CEA) or Cost-Utility analysis 
(CUA), which reports a non-monetary value as an outcome, such as the “percentage 
reduction in certain condition” or “quality-adjusted life years saved”. Cost-benefit analysis 
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(CBA) reports simply a monetary value as an outcome. These are the most commonly used 
methods of validating the potential cost-effectiveness from a number of interventions in 
health economics (Haddix et al. 2013).  
 
In our literature review, we look to focus mainly on the CUA and CBA analysis. These 
analysis methods are vastly used in the latest research, since they are robust and applicable to 
multiple conditions simultaneously, and their basic mechanisms differ from each other. We’ll 
briefly describe CEA in order to get an understanding of how CUA differs from it and how 
can CUA be seen as more applicable in research of complex systems, a dynamically changing 
system with multiple components that affect each other such as health. This might be the 
reason why CUA is often used in the latest studies.  
3.2.1 Cost-effectiveness analysis (CEA) 
CEA is historically the most common analysis method in the field of health economics. CUA 
can be labeled under the CEA model which both report a non-monetary value as an outcome 
unlike CBA (Haddix et al. 2013). CEA reports health outcome of an intervention as a natural 
unit of measure such as “%- reduction of the population suffering from obesity” after 
treatment or a more generic outcome such as “life years gained” after the intervention. CEA 
is defined as dividing the net costs by the net effectiveness of a treatment intervention.  
 
Net cost equals the cost of implementation or the calculated programmatic costs minus the 
costs averted through the preventive intervention. 
(1) 
𝑵𝑪 = 𝑃𝐶 − 𝐶𝑂𝐼 
 
𝑁𝐶 = 𝑁𝑒𝑡 𝑐𝑜𝑠𝑡𝑠 
𝑃𝐶 = 𝑃𝑟𝑜𝑔𝑟𝑎𝑚𝑚𝑎𝑡𝑖𝑐 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑎𝑛 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛  
𝐶𝑂𝐼 = 𝐶𝑂𝐼 𝑎𝑣𝑒𝑟𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑛𝑒𝑤 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 
 
A preventive care intervention that decreases the overall costs is referred to as cost-saving 
intervention. If benefits of certain preventive care interventions are sufficiently larger 
compared to its costs, the intervention is defined as cost-effective intervention even it 
wouldn’t save money (Cohen & Neumann 2009). If net cost returns a negative value (positive 
value) the costs of the intervention are lower (higher) than the status quo treatment method. 
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In such cases, the cost-effectiveness is presented as net cost savings (cost-effectiveness 
ratio.).  
 
Net effectiveness equals the health outcomes of putting in place the intervention minus the 
health outcomes without the intervention. 
(2) 
𝑵𝑬 = 𝑂𝐴 − 𝑂𝐵 
 
𝑁𝐸 = 𝑁𝑒𝑡 𝑒𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑖𝑛𝑒𝑠𝑠 
𝑂𝐴 = 𝐻𝑒𝑎𝑙𝑡ℎ 𝑜𝑢𝑡𝑐𝑜𝑚𝑒𝑠 𝑤𝑖𝑡ℎ 𝑡ℎ𝑒 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 
𝑂𝐵 = 𝐻𝑒𝑎𝑙𝑡ℎ 𝑜𝑢𝑡𝑐𝑜𝑚𝑒𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑡ℎ𝑒 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 
 
For example, in the case of preventing the occurrence of obesity, Outcomes A represents the 
hypothetically calculated average value of the potential change of obesity within the targeted 
group. Outcomes B represents the current change of obesity within the targeted group with 
the status quo treatment method.   
 
Finally, if net costs equal a positive value the cost-effectiveness ratio (CE) is presented using 
the following formula (3):  
 
(3) 






If the net costs equal a negative value the cost-effectiveness is presented as cost-savings and 
calculated with the following formula (4): 
  
(4) 
𝑁𝐶𝑆 = 𝑃𝐶 − 𝐶𝑂𝐼 
 
𝑁𝐶𝑆 = 𝑁𝑒𝑡 𝑐𝑜𝑠𝑡 𝑠𝑎𝑣𝑖𝑛𝑔 
𝑃𝐶 = 𝑃𝑟𝑜𝑔𝑟𝑎𝑚𝑚𝑎𝑡𝑖𝑐 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑎𝑛 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛  





CEA or some of its modifications such as CUA are the most commonly used analysis 
methods in the field of health economics and economic evaluation calculations. A study 
conducted by Schwappach; Boluarte & Suhrcke (2007) showed that from 195 papers that 
studied the cost-effectiveness of cardiovascular disease interventions, CEA (reported as 
clinical outcome or as life years saved) was used as a primary economic evaluation method in 
65% of all papers. In contrary Drummond et al. (2015) claim in their study that in more 
recent literature CEA is less used due to preferable method guidelines provided by 
Washington Panel and official requirements provided by the National Institute for Health and 
Care Excellence (NICE).  
3.2.2 Cost-utility analysis (CUA) 
The Cost-Utility analysis (CUA) is used to determine the cost in terms of utilities measured 
in quantity and quality of life. CUA is used in order to make analysis outcomes of an 
intervention more generic compared to CEA which measures the health outcomes in purely 
natural units and is not comparable between two different health outcomes. The potential 
health outcomes of CUA are usually expressed in Quality of Adjusted Life Year (QALY) or 
Disability Adjusted Life Year (DALY).   
 
A study conducted by Prieto & Sacristán (2003) well demonstrates how QALYs are 
calculated. QALY is a coefficient scale from 0 representing death to 1 representing a year in 
perfect health. A year lived in perfect health equals 1 QALY. A year lived in suffer, caused 
by a disease or condition that causes harm to the quality of life for example by 40% equals 
0.6 QALY.  
 
The value of QALY coefficient in a given health state is evaluated from the population or the 
intervention target group by multiple ways, such as Standard Gamble, Time Trade-Off, 
Rating Scale, or by means of pre-scored health state sorting systems (i.e. HUI, EQ-5D) 
(Prieto & Sacristán 2003). According to McDaid et al. (2015) in most developed countries, 
especially in the EU region QALYs are estimated using a EuroQol or EQ-D5™ evaluation 
questionnaire.  
 
EQ-D5™ is a standardized instrument self-reported by the respondent to measure the current 
state of health in its respondents with various kinds of health diseases and conditions. 
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Information derived from the respondents' answers is evaluated as his or her health state on a 
scale from 0 to 1. These coefficients formed from the EQ-D5™ scale represent QALYs 
(Prieto & Sacristán 2003). The EQ-5D™ questionnaire has two sections, a panel of 5 
standard questions: mobility, self-care, pain, anxiety, and daily activities and the other section 
consisting of a thermometer like single index (VAS) to value individuals current health state 
from 0 to 100 (McDaid et al 2015). 
 
In order to perform a CUA and compare different treatment methods Prieto & Sacristán 
(2003) lists an example demonstration of CUA calculation in Figures 1 and 2. In their 
example they use two alternative treatment methods, their costs and QALYs gained through 
the treatment method. In the example, QALYs are estimated by treatment A increasing the 
quality of life from 0.5 to 0.9 and the quantity of life by 2 years (3.6 QALYs). The 
incremental costs are calculated by costs of treatment A ($1500) minus the costs of treatment 
B ($1000). Incremental outcomes, additional QALYs are calculated similarly.  
 
Finally, CUA is calculated by dividing the Incremental costs with the incremental outcomes 
and reported as costs per QALY gained ($192.31).  
 
In other words, this analysis assumes that treatment A compared to treatment B would 
enhance the quality of life of an individual from 0.5 to 0.9 and add two more life years. This 
intervention would then cost 192.31 dollars per year.  
 
 






Figure 2. Cost Utility example visualized. Source: Prieto & Sacristán (2003).   
 
 
CUA is the second most used analysis method in health economics. Many researchers suggest 
the usage of CUA and claims it is the best possible analysis method available (Robinson 
1993; Drummond. et al 2015). From 195 cardiovascular disease interventions, 20% reported 
outcomes with CUA (Schwappach et al. 2007). Additionally, in high-income countries, 
QALY is the most commonly used generic outcome measure (Haddix et al. 2013).  
 
CUA provides a generic measure of health outcomes (QALYs) for comparison of costs and 
outcomes between different programs (Drummond et al. 2015). This makes CUA more 
applicable and robust in analyzing the potential effectiveness and outcomes compared to 
CEA. CEA only reports the outcomes as natural units and leaves a lot of room in capturing 
the spillover effects of other comorbidities related to certain diseases. Additionally, CEA 
doesn’t allow the simultaneous comparison of multiple interventions. Both CUA and 
especially CEA are hard to interpret by policymakers since they use non-monetary values as 
outcomes. We’ll discuss more of this challenge in the next chapters.  
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3.2.4 Cost-benefit analysis 
The Cost-Benefit Analysis (CBA) is often considered as the golden standard in basic 
economic evaluations (Haddix et al. 2013). The advantage of CBA is that it uses common 
metrics that can usually be expressed in monetary value, which enables effective ways of 
comparing a health care intervention and its costs and potential benefit in other societal 
sectors such as infrastructure, national defense and such. This is why CBA is mostly utilized 
amongst policymakers deciding where to invest and budget generally (CDCb). In contrary 
McDaid et al (2015) argues that CBA method that often comes across in multiple economic 
evaluations is rarely used in the healthcare sectors, where evaluating benefits that 
incrementally increased health would achieve is challenging.  
 
In terms of evaluating if certain preventive health care intervention has the possibility to 
return a positive investment CBA compares the society’s willingness to pay for a certain 
health intervention with the opportunity costs. Such opportunity costs can for example 
present the lost monetary value that could have been used in something else what was 
sacrificed with the investment for a better health outcome.  
 
In order to estimate the CBA of an intervention we need to map out the total future costs and 
the total future benefits associated with the intervention over time. Present values are 
calculated as following: 
 
(5)  















𝑃𝑉𝐶 = 𝑃𝑟𝑒𝑠𝑒𝑛𝑡 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑓𝑢𝑡𝑢𝑟𝑒 𝑐𝑜𝑠𝑡𝑠 
𝑃𝑉𝐵 = 𝑃𝑟𝑒𝑠𝑒𝑛𝑡 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑓𝑢𝑡𝑢𝑟𝑒 𝑏𝑒𝑛𝑒𝑓𝑖𝑡𝑠 
𝑟 = 𝑑𝑖𝑠𝑐𝑜𝑢𝑛𝑡 𝑟𝑎𝑡𝑒 
𝑡 = 𝑦𝑒𝑎𝑟𝑠 𝑜𝑓 𝑖𝑛𝑠𝑝𝑒𝑐𝑡𝑖𝑜𝑛 




Net present value (NPV) or a benefit-cost ratio (BCR) can be used in modeling CBA:  
 
(6) 







Measured in NPV, the invested health intervention is efficient if the present value of total 
future benefits exceeds the total future costs. This equals the net benefits. Measurement of net 
benefits can be then compared to other interventions and activities and seen which one of the 
possible interventions show the strongest proof of being efficient. Measured in CBR, values 
exceeding 1 show proof that the benefits of the calculated interventions exceed the potential 
costs. 
 
CBA uses monetary values in both the numerator and divisor which makes its very nature 
different to CEA and CUA. CBA compared to other economic evaluation methods is more 
adjustable in comparing a wide range of public programs (Haddix et al. 2013). This makes it 
an often-used method amongst policymakers, which might cause a potential 
miscommunication between policymakers and researchers. While researchers are trying to 
find cost-effective interventions, policymakers are looking for cost-saving interventions 
(CDCa). This potentially leads into miscommunication between the two different parties and 
could be the reason for a slower adaptation of preventive healthcare services. Preventive 
healthcare services are often more costly on the surface as seen moderately in the example in 
figure 1 and 2 by Prieto & Sacristán (2003) but might have societal value and hold long term 
benefit to the society.  Additionally, giving a monetary value for health benefits is a challenge 
the researchers using CBA tools usually face. Previously mentioned problems, as well as 
other limitations and challenges that cost-effectiveness analyses face will be discussed more 






4. Challenges related to economic evaluation in preventive 
healthcare interventions 
 
Many studies in the field of health economics have studied the challenges in economic 
evaluation of healthcare interventions such as Handels & Wimo (2019) ; Steel et al (2018). 
Many of these studies have had very similar kind of findings of the missing costs, potential 
effectiveness and value that these models are unable to capture. The studies analyzed and the 
economic evaluation methods used have challenges taking into consideration many key 
aspects that standard economic analyses should. According to Handels & Wimo (2019) the 
aspects the current models and research are having challenges to capture are; the long-term 
effects of prevention, if prevention saves money in the long term and how much do these 
interventions have an impact on the quality of life. Similar concerns were shown by Cohen & 
Neumann (2009) and the challenges of economic evaluation models estimating if the total 
lifetime costs of prevention would actually save money. Handels & Wimo (2019) highlight 
other factors such as; indirect effects on the quality of life through prevention, such as other 
diseases that may have an effect on the same time that certain condition is being treated. 
Other topics highlighted are the discounting rate over time, optimized target group and 
mapping all the intervention costs. Multiple researchers in previous studies in the field have 
studied and come across multiple other challenges about the economic evaluation which will 
be discussed in more detail in the following chapters. 
4.1 Randomized controlled trials as the status quo 
Randomized controlled trials (RCT) can be seen as a status quo in many fields of research. In 
the realm of healthcare randomized controlled trials can be seen as questionable way of 
conducting research. McDaid et al. (2015) argue that RCTs may have an effect and 
potentially damage the outcomes of the research. Randomizing patients within a treatment 
and control group may be challenging to implement when dealing with complex interventions 
and health-promoting interventions that happen in real life may be hard to control. Such 
interventions could, for example, be reducing cardiovascular disease with physical exercise. 
A control group having an exercise limit of 2 hours a week versus a treatment group with 4 
hours a week. Is it appropriate and how realistic is it to limit the other groups exercise time 
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when the research is not being conducted in a laboratory setting? Many researchers have 
argued against such claims, stating RCT’s being as applicable to healthcare than in any other 
field of research. For example, Rosen et al. (2006) argue that RCT’s can be modified and 
designed in order to answer the needs of the research conducted and fit well into the realm of 
health care research.  
 
Depending on how RCT’s are being conducted, RCT’s might steer the results of the cost-
effectiveness of preventive treatment. While preventive health care services usually reap 
results after a long period of time, RCTs that have highly restricted variables, that need to be 
controlled over a long period of time, might inflate the programmatic costs of potential 
intervention and eat out some of the cost-effectiveness of the intervention and return 
unfavorable results before wider implementation of the intervention.  
4.2 Estimating the value for QALY 
In recent research, there has been a lot of criticism in terms of QALY and how it’s evaluated. 
How should we estimate the quality of life measured and give QALY a value that can be 
compared to when conducting economic evaluation. How does one give a value for the 
quality of life, what are the factors that have an effect on a person’s quality of life? McDaid 
et al. (2015) state that the main criticism towards QALYs in the field is due to the fact that 
QALYs only capture health-related quality of life, ignoring plenty of the other factors that 
may have an influence on one's assumption of “quality of life”, such as education, safety, and 
other factors.  
 
The threshold value range of QALY is 50,000 to 100,000 and this range of values is being 
used in the field of health care as a decision rule amongst policymakers (Cohen & Neumann 
2009). Meaning that preventive interventions that represent lower QALY values, smaller than 
50,000 to 100,000 per QALY would be seen as cost-effective, from the eyes of policy 
makers. Many researchers have criticized the threshold values claiming them to be too strict 
and suggesting of increasing the threshold value of QALY that seems to be undervalued in 
the modern era. Braithwaite et al. (2008) proposed after conducting a sensitivity analysis that 
raising the QALY threshold from range of 50,000-100,000 to 95,000 to 267,000 dollars per 
QALY would give a more realistic image of the value of one quality-adjusted life year in the 
modern era, claiming that the older values have been conducted and formed in much older era 
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of time and them lacking empirical proof. This might result the lack of preventive health care 
services being implemented, since the threshold values are so low that it’s hard to find any 
cost-effective interventions that might represent such small values.   
 
Also, some researchers have tackled and criticized the way QALYs are calculated. Prieto & 
Sacristán (2003) claimed that comparing time and quality is misleading and leads to 
contradicting results. Time and quality are very different types of parameters and should not 
be given a combined numerical coefficient or combined value since their very nature differs 
so much. 
4.3 Estimating total lifetime costs 
Estimating the total lifetime costs and benefits of prevention can be very challenging. In 
England when developing the National Institute of Health and Care Excellence (NICE) 
guidelines for evidence-based public health the estimation of time horizon and the causality 
between intervention and outcomes was described as one of the key challenges in economic 
evaluation (McDaid et al. 2015). Prevention and the intervention related may have a long 
time period before they demonstrate positive outcomes and the costs may be significantly 
higher in the beginning compared to the outcomes. The choice of time horizon in economic 
evaluation may drastically affect the outcomes of the cost-effectiveness analysis. McCreesh 
et al. (2018) studied how the choice of time horizon might hold a crucial effect on the 
effectiveness of prevention of HIV occurrence in Uganda. The study showed that intervention 
within 4 years from 2014-2018 didn’t show drastic cost-effectivity but was very highly likely 
to be cost-effective in 2030. Many aspects need to be taken into consideration when 
estimating total lifetime costs, such as the used discount rates in a given analysis - how much 
are costs and benefits that would occur through the intervention within 30-50 years valued 
today? The use of optimal discount rates in economic evaluation is discussed in multiple 
studies, many researchers use the inflation-adjusted, long-term risk-free return on capital rate 
(3%). In each prevention intervention, depending on the researcher’s choice, utilization and 
choice of discount rate may have a significant impact on the economic evaluation and the 





Additionally, what Cohen & Neumann (2009) interpret as “competing risk” in their research 
is a significant factor looking at cost-effectiveness calculations and how they hold in general. 
Naturally increasing prevention-based treatment makes populations less prone to variety of 
chronic diseases and enables people to live longer. This means that the life-span of humans 
would increase, which has inarguably been one of the humankind's biggest achievements. 
Looking at this matter from an economic and societal perspective provides an alternative and 
arguing viewpoint on the matter. Added life years comes with a price, the price of additional 
costs and an overall economic burden to society. Prevention adds life years and these added 
life years especially in the late years can be extremely costly to the society. According to 
Alemayehu et al. (2004) annual healthcare costs start rising exponentially after the age of 50 
and comparing 85 years or older to 75-84 years old population the annual health care costs 
are twice as much in the former group. Prevention effectiveness thus depends on how much 
prevention in the population that the intervention is targeted can in earlier phases of their 
lifetime decrease direct costs occurring from a variety of preventable diseases and conditions 
and indirect costs such as productivity losses.  
4.4 Estimating the outcomes of avoiding related comorbidities 
Many of the current analysis methods related to the effectiveness of prevention interventions 
are lacking the capability of capturing the potential savings of avoiding comorbidities related 
to certain diseases or condition if the intervention is set in place. In other words, for example 
preventive interventions targeted to decrease the occurrence of Diabetes Mellitus Type 2 in 
adolescents by recommending and increasing physical activity and recommending cleaner 
diet might lower the risk of hypertension and cardiovascular diseases and countless of other 
conditions. If such analysis was conducted and one would be able to analyze the costs averted 
by avoiding the occurrence of related comorbidities the cost-effectiveness analysis would 
show much more positive results, than the current models that usually measure one condition 
or disease at a time as is seen in CEA’s, which reports outcomes in natural units one 
condition at a time. CUA analysis can be argued to capture this since it converts the natural 
units of outcomes to QALYs and captures through earlier discussed methods such as EQ-
D5™ the state of populations health with a certain disease. This in some extent might take 
into consideration the most common comorbidities related to certain condition that is the 





5.5 Capturing spillover effects 
Capturing spillover effects of either from an existing condition or spillover effects that are 
caused or are a result of preventive healthcare interventions is vastly researched topic such as 
Basu & Meltzer. D. (2005); Prosser et al. (2014). It’s described by many researchers as a 
challenging task to capture and is thus often disregarded in economic evaluation. Including or 
excluding the analysis of potential spillover effects might change drastically the cost-
effectiveness ratio of an intervention. Al-Janabi et al. (2016) measured the spillover effects in 
families that had one member of the family that suffered from meningitis, acute inflammation 
of membranes covering the brain. They found that the closest and even some distinct family 
members suffered from various kinds of health issues and overall health status loses 
measuring health status with the EQ-D5™ questionnaire. The research reported that 
vaccinating against meningitis would increase the health status of the family members 
network by 16% or 0.041 annual QALYs. Estimating spillover effects in examples like such 
and the costs that such conditions in a family network might cause to the society should be 
taken into consideration in COI analysis but rarely are. This could drastically change the 
results of how severe some of the diseases are and encourage towards the adaption of 
prevention.  
 
We can analyze potential spillover effects from another perspective as well. How much 
would introducing a preventive intervention to treat certain condition impact on the whole 
society through close members of the targeted individual or population?  McDaid et al. 
(2015) in their report argue that adding preventive healthcare services might have a positive 
effect on the broader population through close family members adapting, for example, a 
certain kind of lifestyle and influencing other people around them to take similar actions. 
These kinds of factors aren’t usually taken into consideration in economic evaluation since 
research as such is challenging to conduct and additionally is likely to be highly expensive 
eating out the cost-effectiveness of a given intervention, since these costs would be naturally 









This literature review illustrates the current state of preventive healthcare in developed 
countries, the tools which economic evaluation is being conducted in the field as well as the 
limitations of these tools and common pitfalls in measuring the costs and outcomes of 
healthcare interventions. This study proposes that the lingering reason for the poor adoption 
of preventive health care services provided to society is due to the fact that the economic 
evaluation and research conducted in the field are lacking the ability to capture some of the 
underlying value and factors affecting society's health analyzed in Chapter 4 and 5. The 
research and existing tools seem lack the ability in capturing the potential value that 
prevention could potentially create. How prevention might affect more efficiently in curing 
other comorbidities associated with a certain disease, compared to treating a specific disease 
with treatment-based methods. How prevention might have an effect on the general 
population through a multiplying factor, influencing as an example, better lifestyle choices to 
family members extending from them to even further (McDaid et al. 2015). Additionally, 
these tools and research seem to have problems in estimating the total costs over long periods 
of time that prevention might take in order to manifest positive results as seen in the example 
in chapter 5 preventing the occurrence of HIV in Uganda. (McCreesh et al. 2018).  
 
Secondly, between multiple stakeholders, researchers, economists, and policymakers 
involved in the field exists a barrier of communication of the ways how the effectiveness of 
prevention is being measured discussed in chapter 3.2. While policymakers are looking for 
solutions that would save costs researchers and economists are trying to find the most cost-
effective preventive interventions that don’t necessarily save money but are indeed cost-
effective (Cohen & Neumann 2009). Recognizing the limitations of these tools, taking them 
into account and breaking the barrier of communication by forming a mutual understanding 
and common guidelines of measuring the cost-effectiveness of preventive healthcare 







The development of preventive healthcare is slowing down (Wang 2018) and even the cost-
effectiveness and the possible improvements prevention could provide is heavily studied and 
suggested amongst researchers, prevention is not being implemented on the magnitude that 
researchers in the field are proposing. The goal of my research is to raise a concern, a concern 
about the lack of resources invested in preventive healthcare services. I look to raise 
awareness on the topic by providing a wireframe like description of the tools used in the field 
of health economics, by introducing the currently used analysis methods, limitations of these 
methods and the usual pitfalls in designing research settings related to prevention 
effectiveness studies.  
 
With providing this information I look to inspire and promote on further research of the topic, 
leading to the urge of developing more suitable models in economic evaluation that would 
better fit to the field of healthcare, taking into consideration some of the limitations and 
assumptions addressed in this literature review. I assume and wish this would lead to more 
favorable results in terms of the effectiveness of prevention, and finally a wider adoption of 
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